3-(Azepan-1-yl)-1-naphthalen-1-ylpyrrolidine-2,5-dione

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 3-(Azepan-1-yl)-1-naphthalen-1-ylpyrrolidine-2,5-dione
• 化学式: C₂₀H₂₂N₂O₂
• 分子量: 322.4
• InChiKey: XZGDXKWJMZQFNV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  24
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  40.6
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• Dimethylarginine Dimethylaminohydrolase Inhibitors and Methods of Use Thereof
  申请人：University The Board of Trustees of the Leland Stanford Junior

  公开号：US20130224259A1

  公开（公告）日：2013-08-29

  The present disclosure provides DDAH modulators. Thus, the present disclosure provides a method of treating a patient suffering from a disorder characterized by excessive NO production and/or elevated DDAH activity, the method comprising administering to said patient an effective amount of a compound of one of formulae I-X. The present disclosure also provides a pharmaceutical composition comprising a compound of one of formulae I-X.
• US9011882B2
  申请人：——

  公开号：US9011882B2

  公开（公告）日：2015-04-21
• [EN] DIMETHYLARGININE DIMETHYLAMINOHYDROLASE INHIBITORS AND METHODS OF USE THEREOF<br/>[FR] INHIBITEURS DE DIMÉTHYLARGININE DIMÉTHYLAMINOHYDROLASE ET PROCÉDÉS D'UTILISATION ASSOCIÉS
  申请人：UNIV LELAND STANFORD JUNIOR

  公开号：WO2013123033A1

  公开（公告）日：2013-08-22

  The present disclosure provides DDAH modulators. Thus, the present disclosure provides a method of treating a patient suffering from a disorder characterized by excessive NO production and/or elevated DDAH activity, the method comprising administering to said patient an effective amount of a compound of one of formulae I-X. The present disclosure also provides a pharmaceutical composition comprising a compound of one of formulae I-X.
• [EN] DIMETHYLARGININE DIMETHYLAMINOHYDROLASE INHIBITORS AND METHODS OF USE THEREOF<br/>[FR] INHIBITEURS DE DIMÉTHYLARGININE DIMÉTHYLAMINOHYDROLASE ET LEURS PROCÉDÉS D'UTILISATION
  申请人：UNIV LELAND STANFORD JUNIOR

  公开号：WO2014160947A1

  公开（公告）日：2014-10-02

  The present disclosure provides DDAH modulators. Thus, the present disclosure provides a method of treating a patient suffering from a disorder characterized by excessive NO production and/or elevated DDAH activity, the method comprising administering to said patient an effective amount of a compound of one of formulae I-X. The present disclosure also provides a pharmaceutical composition comprising a compound of one of formulae I-X.